One of the drug industry’s most prolific dealmakers is striking again to revive eye-care company Bausch + Lomb.

The company said Friday it will pay $1.75 billion to acquire a dry-eye drug from Novartis, the first big move by Chief Executive Brent Saunders since he returned to the helm in March.